Saturday, 27 July 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 27 July 2024
Listen to this story 
News

Top PBS drug facing competition

Posted 8 February 2024 AM

Vertex Pharmaceuticals has revealed it has improved on its jackpot cystic fibrosis medication Trikafta with a "vanza triple", announcing its potential for "halting the disease before it starts" in children.

The company this week reported it would apply to drug regulators in the US and Europe for its once-daily combined treatment of vanzacaftor, tezacaftor and deutivacaftor.

To see the whole article, please login

Popular

Bracing for a $100M revenue hit
$30M quarterly sales left behind
TGA first to add new mRNA jab AE
Thumbs down for pharma websites
Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (27)

Clinical & Medical, R&D (18)

Regulatory, Pharmacovigilance & QA (7)

Other (25)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home